HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Silence Therapeutics (NASDAQ:SLN) and maintained a price target of $75.
May 17, 2024 | 5:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Silence Therapeutics and maintained a price target of $75, indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in Silence Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100